

paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

### *Amendments*

#### *In the Claims:*

Please substitute the following claims 157, 173, 176, 180, 196, 199, 207, 210, 229, 230, 231, 232, 236, 239, 247, 250, 257, 260, 264, 273, 276, 280 and 288 for pending claims 157, 173, 176, 180, 196, 199, 207, 210, 229, 230, 231, 232, 236, 239, 247, 250, 257, 260, 264, 273, 276, 280 and 288:

157. (Once amended) An isolated polynucleotide comprising a first nucleic acid at least 90% identical to a reference nucleic acid selected from the group consisting of:

- (a) a nucleic acid consisting of nucleotides 839 to 1048 of SEQ ID NO:1;
- (b) a nucleic acid consisting of nucleotides 419 to 1420 of SEQ ID NO:1;
- (c) a nucleic acid consisting of nucleotides 416 to 1420 of SEQ ID NO:1;

and

- (d) a nucleic acid consisting of the nucleotides encoding the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 203072;

wherein said first nucleic acid encodes a polypeptide that regulates Prostate-Specific Antigen (PSA) gene expression.

173. (Once amended) The vector of claim 172, wherein said first nucleic acid is associated with a heterologous sequence.

176. (Once amended) The host cell of claim 175, wherein said first nucleic acid is associated with a heterologous sequence.

180. (Once amended) An isolated polynucleotide comprising a nucleic acid encoding a first amino acid sequence at least 90% identical to a reference amino acid sequence selected from the group consisting of:

- (a) amino acids 142 to 211 of SEQ ID NO:2;
- (b) amino acids 2 to 335 of SEQ ID NO:2;
- (c) amino acids 1 to 335 of SEQ ID NO:2; and

(d) the complete amino acid sequence encoded by the cDNA clone contained in ATCC Deposit No. 203072; wherein said first amino acid sequence regulates Prostate-Specific Antigen (PSA) gene expression.

196. (Once amended) The vector of claim 195, wherein said first nucleic acid is associated with a heterologous sequence.

199. (Once amended) The host cell of claim 198, wherein said first nucleic acid is associated with a heterologous sequence.

207. (Once amended) The vector of claim 206, wherein said first nucleic acid is associated with a heterologous sequence.

210. (Once amended) The host cell of claim 209, wherein said first nucleic acid is associated with a heterologous sequence.

229. (Once amended) An isolated polynucleotide comprising a first nucleic acid at least 95% identical to a nucleic acid encoding at least 100 contiguous amino acids of SEQ ID NO:2; wherein said first nucleic acid encodes a polypeptide that regulates Prostate-Specific Antigen (PSA) gene expression.

230. (Once amended) An isolated polynucleotide comprising a nucleic acid encoding at least 100 contiguous amino acids of SEQ ID NO:2.

231. (Once amended) The isolated polynucleotide of claim 229, comprising a nucleic acid encoding at least 150 contiguous amino acids of SEQ ID NO:2.

232. (Once amended) The isolated polynucleotide of claim 230, comprising a nucleic acid encoding at least 150 contiguous amino acids of SEQ ID NO:2.

236. (Once amended) The vector of claim 235, wherein said first nucleic acid is associated with a heterologous sequence.

239. (Once amended) The host cell of claim 238, wherein said first nucleic acid is associated with a heterologous sequence.

247. (Once amended) The vector of claim 246, wherein said first nucleic acid is associated with a heterologous sequence.

250. (Once amended) The host cell of claim 249, wherein said first nucleic acid is associated with a heterologous sequence.

257. (Once amended) The vector of claim 256, wherein said first nucleic acid is associated with a heterologous sequence.

260. (Once amended) The host cell of claim 259, wherein said first nucleic acid is associated with a heterologous sequence.

264. (Once amended) A polynucleotide comprising a nucleic acid fused in frame to a nucleotide sequence heterologous to SEQ ID NO:1, wherein said heterologous nucleotide sequence encodes a heterologous polypeptide, and wherein said nucleic acid is selected from the group consisting of:

- (a) a nucleic acid encoding amino acids 279 to 287 of SEQ ID NO:2;

- (b) a nucleic acid encoding amino acids 292 to 300 of SEQ ID NO:2;
- (c) a nucleic acid encoding amino acids 317 to 325 of SEQ ID NO:2;
- (d) a nucleic acid encoding amino acids 239 to 247 of SEQ ID NO:2;
- (e) a nucleic acid encoding amino acids 272 to 280 of SEQ ID NO:2; and
- (f) a nucleic acid encoding amino acids 248 to 331 of SEQ ID NO:2.

273. (Once amended) The vector of claim 272, wherein said nucleic acid is associated with a heterologous sequence.

276. (Once amended) The host cell of claim 275, wherein said nucleic acid is associated with a heterologous sequence.

280. (Once amended) An isolated polynucleotide comprising a nucleic acid encoding at least 60 contiguous amino acids of SEQ ID NO:2;  
wherein said nucleic acid is associated with a heterologous sequence selected from the group consisting of a promoter, a site for transcription initiation, a site for transcription termination, an enhancer, a Kozak sequence, an operator and a ribosome binding site.

288. (Once amended) A polynucleotide comprising a nucleic acid fused to a nucleotide sequence heterologous to SEQ ID NO:1, wherein said heterologous nucleotide sequence encodes a heterologous polypeptide, and wherein said nucleic acid is selected from the group consisting of:

- (a) a nucleic acid encoding amino acids 279 to 287 of SEQ ID NO:2;

- (b) a nucleic acid encoding amino acids 292 to 300 of SEQ ID NO:2;
- (c) a nucleic acid encoding amino acids 317 to 325 of SEQ ID NO:2;
- (d) a nucleic acid encoding amino acids 239 to 247 of SEQ ID NO:2;
- (e) a nucleic acid encoding amino acids 272 to 280 of SEQ ID NO:2; and
- (f) a nucleic acid encoding amino acids 248 to 331 of SEQ ID NO:2;

wherein said nucleic acid is operatively associated with a promoter to express said amino acids.